GamaMabs Pharma SA:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:GamaMabs Pharma SA - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C11305
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:20
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:フランス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
GamaMabs Pharma SA (GamaMabs) is a clinical-stage immuno-oncology company that develops optimized therapeutic antibodies for the treatment of cancer. The company’s lead product candidate GM102, is an anti-AMHR2, Emabling engineered humanized mAb product targeting the receptor of anti-Mullerian hormone (AMH) in gynecological cancers. It develops its products through EMABling, HuMabFc platforms, and others. GamaMabs’s products find therapeutic applications in the areas of ovarian and endometrium cancer among others. The company works in partnership with academic partners and other research centers such as Institut Gustave Roussy, Institut Curie, Institut Cochin, Institut de Recherche en Cancerologie de Montpellier and Mass General Hospital Boston. GamaMabs is headquartered at Toulouse, France.

GamaMabs Pharma SA – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
GamaMabs Pharma SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
GamaMabs Pharma SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
GamaMabs Pharma SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
GamaMabs Pharma SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
GamaMabs Pharma SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
GamaMabs Pharma SA, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
GamaMabs Pharma Raises USD16 Million in Series B Financing 10
GamaMabs Pharma Raises USD0.7 Million in Venture Financing 11
GamaMabs Pharma Raises USD5 Million in Series A Financing 12
GamaMabs Pharma Raises US$4.2 Million In Seed Financing 13
Partnerships 14
Curie-Cancer Extends Co-Development Agreement with GamaMabs Pharma 14
Curie-Cancer Enters into Co-Development Agreement with GamaMabs Pharma 15
Licensing Agreements 16
GamaMabs Enters into Licensing Agreement with MedImmune 16
GamaMabs Pharma SA – Key Competitors 17
GamaMabs Pharma SA – Key Employees 18
GamaMabs Pharma SA – Locations And Subsidiaries 19
Head Office 19
Appendix 20
Methodology 20
About GlobalData 20
Contact Us 20
Disclaimer 20

List of Tables
GamaMabs Pharma SA, Pharmaceuticals & Healthcare, Key Facts 2
GamaMabs Pharma SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
GamaMabs Pharma SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
GamaMabs Pharma SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
GamaMabs Pharma SA, Deals By Therapy Area, 2012 to YTD 2018 8
GamaMabs Pharma SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
GamaMabs Pharma Raises USD16 Million in Series B Financing 10
GamaMabs Pharma Raises USD0.7 Million in Venture Financing 11
GamaMabs Pharma Raises USD5 Million in Series A Financing 12
GamaMabs Pharma Raises US$4.2 Million In Seed Financing 13
Curie-Cancer Extends Co-Development Agreement with GamaMabs Pharma 14
Curie-Cancer Enters into Co-Development Agreement with GamaMabs Pharma 15
GamaMabs Enters into Licensing Agreement with MedImmune 16
GamaMabs Pharma SA, Key Competitors 17
GamaMabs Pharma SA, Key Employees 18

List of Figures
GamaMabs Pharma SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
GamaMabs Pharma SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
GamaMabs Pharma SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
GamaMabs Pharma SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
GamaMabs Pharma SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
GamaMabs Pharma SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
GamaMabs Pharma SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
GamaMabs Pharma SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[GamaMabs Pharma SA:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Sentara Healthcare Inc:企業の戦略的SWOT分析
    Sentara Healthcare Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Pteris Global Ltd:企業の戦略・SWOT・財務情報
    Pteris Global Ltd - Strategy, SWOT and Corporate Finance Report Summary Pteris Global Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • RegenxBio Inc (RGNX):企業の財務・戦略的SWOT分析
    RegenxBio Inc (RGNX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • El Paso Electric Company (EE):電力:M&Aディール及び事業提携情報
    Summary El Paso Electric Company (El Paso) is a vertically integrated electric utility, which generates, transmits, and distributes electric power. It produces electricity from nuclear, natural gas, coal, and solar sources. The company has ownership interest in and operates various power generation …
  • PharmaEssentia Corp (6446)-製薬・医療分野:企業M&A・提携分析
    Summary PharmaEssentia Corp (PharmaEssentia) is a research and development company that develops therapeutic products for the treatment of human diseases. The company’s pipeline product include P1101, a new generation PEG-Interferon-alpha-2b which is developed using PEGylation technology platform. I …
  • Alibaba Group Holding Limited:戦略・SWOT・企業財務分析
    Alibaba Group Holding Limited - Strategy, SWOT and Corporate Finance Report Summary Alibaba Group Holding Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Ulker Biskuvi Sanayi A.S.:戦略・SWOT・企業財務分析
    Ulker Biskuvi Sanayi A.S. - Strategy, SWOT and Corporate Finance Report Summary Ulker Biskuvi Sanayi A.S. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • IFFCO-Tokio General Insurance Co Ltd:企業の戦略・SWOT・財務分析
    IFFCO-Tokio General Insurance Co Ltd - Strategy, SWOT and Corporate Finance Report Summary IFFCO-Tokio General Insurance Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysi …
  • Integrated BioTherapeutics Inc-製薬・医療分野:企業M&A・提携分析
    Summary Integrated BioTherapeutics Inc (IBT) is a biotechnology company that discovers novel vaccines and therapeutics for infectious diseases. The company's products include polyclonal and monoclonal antibodies raised against various emerging pathogens, vaccines and therapeutics against bacteria, p …
  • SynCore Biotechnology Co Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary SynCore Biotechnology Co Ltd (SynCore), a subsidiary of Sinphar Pharmaceutical Co Ltd is a biopharmaceutial company that new drug by research and development management and integration of technology resources. The company’s pipeline products include SB01, SB02, SB03, SB04 and SB05; and diagn …
  • Vision RT Ltd:企業の戦略的SWOT分析
    Vision RT Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services …
  • IndusInd Bank Ltd:戦略・SWOT・企業財務分析
    IndusInd Bank Ltd - Strategy, SWOT and Corporate Finance Report Summary IndusInd Bank Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Heat Biologics Inc (HTBX):製薬・医療:M&Aディール及び事業提携情報
    Summary Heat Biologics Inc (Heat Biologics) is a biopharmaceutical company which develops novel immuno therapeutics for the treatment of cancer. Its pipeline encompasses viagenpumatucel-L based investigational candidate targeted at the treatment of non-small cell lung cancer, and co-stimulatory anti …
  • Airbus Group SE:企業の戦略・SWOT・財務情報
    Airbus Group SE - Strategy, SWOT and Corporate Finance Report Summary Airbus Group SE - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Yanchang Petroleum International Ltd (346):企業の財務・戦略的SWOT分析
    Yanchang Petroleum International Ltd (346) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengt …
  • Adaptive Biotechnologies Corp:製薬・医療:M&Aディール及び事業提携情報
    Summary Adaptive Biotechnologies Corp (Adaptive) specializes in combining high-throughput sequencing and expert bioinformatics to profile T-cell and B-cell receptors. The company’s product portfolio comprises immunoSEQ and clonoSEQ. It provides immunosequencing platform to laboratories for conductin …
  • Whirlpool Corp (WHR):企業の財務・戦略的SWOT分析
    Whirlpool Corp (WHR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Thai Airways International Public Co Ltd:企業の戦略・SWOT・財務分析
    Thai Airways International Public Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Thai Airways International Public Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT …
  • Foraco International SA (FAR):企業の財務・戦略的SWOT分析
    Summary Foraco International SA (Foraco) is a provider of drilling solutions for mining, energy, water and infrastructure projects. The company's drilling solutions include hydrogeological drilling, deep directional drilling, metallurgical sampling and large diameter drilling. It provides geological …
  • Glory Ltd
    Glory Ltd - Strategy, SWOT and Corporate Finance Report Summary Glory Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆